Exploring Four Atraphaxis Species: Traditional Medicinal Uses, Phytochemistry, and Pharmacological Activities.

Atraphaxis is a genus of flowering plants in the family Polygonaceae, with approximately 60 species. Species of Atraphaxis are much-branched woody plants, forming shrubs or shrubby tufts, primarily inhabiting arid zones across the temperate steppe and desert regions of Central Asia, America, and Australia. Atraphaxis species have been used by diverse groups of people all over the world for the treatment of various diseases. However, their biologically active compounds with therapeutic properties have not been investigated well. Studying the biologically active components of Atraphaxis laetevirens, Atraphaxis frutescens, Atraphaxis spinosa L., and Atraphaxis pyrifolia is crucial for several reasons. Firstly, it can unveil the therapeutic potential of these plants, aiding in the development of novel medicines or natural remedies for various health conditions. Understanding their bioactive compounds enables scientists to explore their pharmacological properties, potentially leading to the discovery of new drugs or treatments. Additionally, investigating these components contributes to preserving traditional knowledge and validating the historical uses of these plants in ethnomedicine, thus supporting their conservation and sustainable utilization. These herbs have been used as an anti-inflammatory and hypertension remedies since the dawn of time. Moreover, they have been used to treat a variety of gastrointestinal disorders and problems related to skin in traditional Kazakh medicine. Hence, the genus Atraphaxis can be considered as a potential medicinal plant source that is very rich in biologically active compounds that may exhibit great pharmacological properties, such as antioxidant, antibacterial, antiulcer, hypoglycemic, wound healing, neuroprotective, antidiabetic, and so on. This study aims to provide a collection of publications on the species of Atraphaxis, along with a critical review of the literature data. This review will constitute support for further investigations on the pharmacological activity of these medicinal plant species.

Pharmacological Properties of Four Plant Species of the Genus Anabasis, Amaranthaceae.

The genus Anabasis is a member of the family Amaranthaceae (former name: Chenopodiaceae) and includes approximately 102 genera and 1400 species. The genus Anabasis is one of the most significant families in salt marshes, semi-deserts, and other harsh environments. They are also renowned for their abundance in bioactive compounds, including sesquiterpenes, diterpenes, triterpenes, saponins, phenolic acids, flavonoids, and betalain pigments. Since ancient times, these plants have been used to treat various diseases of the gastrointestinal tract, diabetes, hypertension, and cardiovascular diseases and are used as an antirheumatic and diuretic. At the same time, the genus Anabasis is very rich in biologically active secondary metabolites that exhibit great pharmacological properties such as antioxidant, antibacterial, antiangiogenic, antiulcer, hypoglycemic, hepatoprotective, antidiabetic, etc. All of the listed pharmacological activities have been studied in practice by scientists from different countries and are presented in this review article to familiarize the entire scientific community with the results of these studies, as well as to explore the possibilities of using four plant species of the genus Anabasis as medicinal raw materials and developing medicines based on them.

Pediatric Extracranial Germ Cell Tumors: Expression of microRNA.

BACKGROUND: Germ cell tumors (GCTs) may occur from the neonatal period to late adulthood, characterized by extensive clinical and pathologic heterogeneity. MicroRNAs are a family of small noncoding RNAs that regulate a wide array of biological processes including carcinogenesis. MicroRNAs may be used for many purposes in clinical diagnostics. Numerous studies have proven the diagnostic value of microRNA371-373 and microRNA302/367 expression in malignant GCT. The diagnostic value of microRNA375 is disputable, because while its value is confirmed by some research data, there are still others denying it. METHODS: The results of our own research on the relative expression of 10 microRNAs, including microRNA375, associated with GCT in the tumor tissues of 84 children and adolescents are presented. RESULTS: In our research, overexpression of microRNA 371-373, 302/367 detected in the group of malignant GCT subtypes. Statistically significant expression of microRNA375 have been defined not only in the group of malignant GCT subtypes, but also in the group of immature teratomas. Among malignant GCTs, high expression of microRNA375 is specific for yolk sac tumors. In the group of seminomas, embryonic carcinomas, and mature teratomas expression of microRNA375 was observed imperceptible, even so the results were statistically insignificant. CONCLUSION: Expression of microRNA 371-373, 302/367 is representative of malignant GCT subtypes. Statistically significant and high expression of microRNA375 attributable for yolk sac tumors and immature teratomas.